- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/495 - Facteur de croissance transformant [TGF]
Détention brevets de la classe C07K 14/495
Brevets de cette classe: 605
Historique des publications depuis 10 ans
|
29
|
35
|
53
|
43
|
56
|
60
|
53
|
46
|
31
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Acceleron Pharma Inc. | 349 |
23 |
| Cue Biopharma, Inc. | 194 |
18 |
| The Johns Hopkins University | 5790 |
14 |
| Biocon Limited | 224 |
13 |
| NGM Biopharmaceuticals, Inc. | 174 |
13 |
| The Regents of the University of California | 20447 |
12 |
| Amgen Inc. | 4318 |
12 |
| Scholar Rock, Inc. | 129 |
11 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3260 |
11 |
| Modernatx, Inc. | 1288 |
9 |
| Mayo Foundation for Medical Education and Research | 3345 |
8 |
| National Research Council of Canada | 1565 |
8 |
| io Biotech ApS | 77 |
8 |
| In3bio Ltd. | 23 |
8 |
| Merck Patent GmbH | 5741 |
7 |
| Immatics Biotechnologies GmbH | 1133 |
6 |
| Notogen, Inc. | 6 |
6 |
| President and Fellows of Harvard College | 6065 |
5 |
| The Brigham and Women's Hospital, Inc. | 2247 |
5 |
| Rutgers, The State University of New Jersey | 1963 |
5 |
| Autres propriétaires | 403 |